These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 8127792)

  • 1. [Erythropoietin and fibrinolysis in uremic patients].
    Małyszko J; Pawlak K; Mazerska M; Małyszko J; Myśliwiec M
    Pol Arch Med Wewn; 1993 Oct; 90(4):267-9. PubMed ID: 8127792
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A study of platelet functions, some hemostatic and fibrinolytic parameters in relation to serotonin in hemodialyzed patients under erythropoietin therapy.
    Malyszko J; Malyszko JS; Borawski J; Rydzewski A; Kalinowski M; Azzadin A; Mysliwiec M; Buczko W
    Thromb Res; 1995 Jan; 77(2):133-43. PubMed ID: 7740505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of long-term erythropoietin therapy on fibrinolytic system in haemodialyzed patients.
    Pawlak K; Pawlak D; Mysliwiec M
    Thromb Res; 2008; 121(6):787-91. PubMed ID: 17869326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Importance of serotonergic mechanisms in the thrombotic complications in hemodialyzed patients treated with erythropoietin.
    Małyszko JS; Małyszko J; Pawlak K; Pawlak D; Buczko W; Myśliwiec M
    Nephron; 2000 Apr; 84(4):305-11. PubMed ID: 10754406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced coagulation and fibrinolysis during treatment with recombinant human erythropoietin in patients undergoing chronic hemodialysis.
    Tomura S; Nakamura Y; Tachibana K; Deguchi F; Ando R; Chida Y; Marumo F
    Blood Purif; 1993; 11(6):370-7. PubMed ID: 8043258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Changes in endothelial vasoactive substances and blood coagulation and fibrinolysis functions under recombinant human erythropoietin therapy in hemodialysis patients].
    Takayama K
    Nihon Jinzo Gakkai Shi; 1993 Feb; 35(2):179-88. PubMed ID: 8315881
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of both coagulation and fibrinolysis in childhood hemolytic uremic syndrome.
    Van Geet C; Proesmans W; Arnout J; Vermylen J; Declerck PJ
    Kidney Int; 1998 Oct; 54(4):1324-30. PubMed ID: 9767551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fibrinolytic capacity in hemodialysis patients treated with recombinant human erythropoietin.
    Aunsholt NA; Ahlbom G; Steffensen G; Glud T
    Nephron; 1992; 62(3):284-8. PubMed ID: 1436339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Some aspects of hemostasis in CAPD patients treated with erythropoietin.
    Małyszko J; Suchowierska E; Małyszko JS; Myśliwiec M
    Kidney Blood Press Res; 2002; 25(4):240-4. PubMed ID: 12424426
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of recombinant human erythropoietin (EPOCH) on the coagulation and fibrinolytic systems and platelet function in pre-dialysis patients with chronic renal failure.
    Kaizu K; Uriu K; Eto S
    Nihon Jinzo Gakkai Shi; 1993 Aug; 35(8):989-97. PubMed ID: 8255011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of recombinant human erythropoietin on fibrinolytic system in children on continuous ambulatory peritoneal dialysis.
    Gündüz Z; Kisaarslan FA; Düsünsel R; Poyrazoglu HM; Saraymen R; Per H
    Adv Perit Dial; 1999; 15():278-82. PubMed ID: 10682118
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of recombinant human erythropoietin on hemostasis, fibrinolysis, and blood rheology in autologous blood donors.
    Biesma DH; Bronkhorst PJ; de Groot PG; van de Wiel A; Kraaijenhagen RJ; Marx JJ
    J Lab Clin Med; 1994 Jul; 124(1):42-7. PubMed ID: 8035101
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human erythropoietin improves the blood platelet phospholipid composition in chronically hemodialyzed patients.
    Krawczyk W; Dmoszyńska A; Marczewski K; Ledwozyw A
    Exp Nephrol; 1995; 3(4):265-6. PubMed ID: 8590040
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of subcutaneous administration of recombinant human erythropoietin on plasma protein C, protein S, and antithrombin III levels in patients on continuous ambulatory peritoneal dialysis.
    Lai KN; Yin JA; Li PK; Yuen PM; Lui SF
    Int J Artif Organs; 1992 May; 15(5):264-8. PubMed ID: 1601509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of recombinant human erythropoietin on hemostatic status in chronic uremic patients.
    Tsao CJ; Kao RH; Cheng TY; Huang CC; Chang SL; Lee FN
    Int J Hematol; 1992 Apr; 55(2):197-203. PubMed ID: 1511168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Platelet aggregation during the recombinant human erythropoietin (rHuEPO) treatment of patients with uremia].
    Mazerska M; Pawlak K; Azzadin A; Małyszko J; Małyszko J; Myśliwiec M; Buczko W
    Pol Arch Med Wewn; 1992 Oct; 88(4):230-7. PubMed ID: 1488323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased fibrinolytic activity during use of oral contraceptives is counteracted by an enhanced factor XI-independent down regulation of fibrinolysis: a randomized cross-over study of two low-dose oral contraceptives.
    Meijers JC; Middeldorp S; Tekelenburg W; van den Ende AE; Tans G; Prins MH; Rosing J; Büller HR; Bouma BN
    Thromb Haemost; 2000 Jul; 84(1):9-14. PubMed ID: 10928462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The effect of erythropoietin on fibrinolysis in hemodialyzed patients].
    Opatrný K; Vít L; Opatrná S; Bodláková B; Sulková S; Opatrný K; Krist'an M
    Cas Lek Cesk; 1995 Mar; 134(5):136-8. PubMed ID: 7728837
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Highly stable plasminogen activator inhibitor type one (VLHL PAI-1) protects fibrin clots from tissue plasminogen activator-mediated fibrinolysis.
    Jankun J; Aleem AM; Selman SH; Skrzypczak-Jankun E; Lysiak-Szydlowska W; Grafos N; Fryer HJ; Greenfield RS
    Int J Mol Med; 2007 Nov; 20(5):683-7. PubMed ID: 17912461
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant human C1-inhibitor prevents non-specific proteolysis by mutant pro-urokinase during optimal fibrinolysis.
    Gurewich V; Pannell R
    Thromb Haemost; 2009 Aug; 102(2):279-86. PubMed ID: 19652878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.